Key statistics
As of last trade TScan Therapeutics Inc (TCRX:NMQ) traded at 0.9693, 9.85% above its 52-week low of 0.8824, set on Dec 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.96 |
|---|---|
| High | 0.9875 |
| Low | 0.9122 |
| Bid | 0.9555 |
| Offer | 0.97 |
| Previous close | 0.932 |
| Average volume | 473.71k |
|---|---|
| Shares outstanding | 56.75m |
| Free float | 52.35m |
| P/E (TTM) | -- |
| Market cap | 52.89m USD |
| EPS (TTM) | -1.12 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 19:38 GMT.
More ▼
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
- TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
- TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
- TScan Therapeutics to Participate in Upcoming Investor Conferences
- TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
More ▼
